中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2008年
9期
1440-1441
,共2页
章慧洁%程硕韬%郭跃萍%张永红
章慧潔%程碩韜%郭躍萍%張永紅
장혜길%정석도%곽약평%장영홍
心房颤动%索他洛尔%胺碘酮
心房顫動%索他洛爾%胺碘酮
심방전동%색타락이%알전동
Atrial fibrillation%Sotalol%Amiodarone
目的 观察对比两种目前临床治疗心房颤动的常用药品的剂量疗效,提供临床治疗的经验.方法 选择门诊心房颤动患者344例,随机按每病种分成两组,分别服用索他洛尔与胺碘酮,调整用药剂量治疗并观察12个月.结果 索他洛尔组与胺碘酮组各为172人,索他洛尔组心房颤动转为窦性心律45人,转复率26.2%,复发5例,转复后窦性心律维持率88.9%;胺碘酮组心房颤动转为窦性心律41人,转复率23.8%,复发2例,转复后窦性心律维持率95.1%.结论 索他洛尔组治疗心房颤动的转复率略高于胺碘酮组,转复后窦性心律维持率胺碘酮组高于索他洛尔组.
目的 觀察對比兩種目前臨床治療心房顫動的常用藥品的劑量療效,提供臨床治療的經驗.方法 選擇門診心房顫動患者344例,隨機按每病種分成兩組,分彆服用索他洛爾與胺碘酮,調整用藥劑量治療併觀察12箇月.結果 索他洛爾組與胺碘酮組各為172人,索他洛爾組心房顫動轉為竇性心律45人,轉複率26.2%,複髮5例,轉複後竇性心律維持率88.9%;胺碘酮組心房顫動轉為竇性心律41人,轉複率23.8%,複髮2例,轉複後竇性心律維持率95.1%.結論 索他洛爾組治療心房顫動的轉複率略高于胺碘酮組,轉複後竇性心律維持率胺碘酮組高于索他洛爾組.
목적 관찰대비량충목전림상치료심방전동적상용약품적제량료효,제공림상치료적경험.방법 선택문진심방전동환자344례,수궤안매병충분성량조,분별복용색타락이여알전동,조정용약제량치료병관찰12개월.결과 색타락이조여알전동조각위172인,색타락이조심방전동전위두성심률45인,전복솔26.2%,복발5례,전복후두성심률유지솔88.9%;알전동조심방전동전위두성심률41인,전복솔23.8%,복발2례,전복후두성심률유지솔95.1%.결론 색타락이조치료심방전동적전복솔략고우알전동조,전복후두성심률유지솔알전동조고우색타락이조.
Objective Curative effect of 2 drugs which present elinie used in atrium filament trembles,provides the elinieal experience.Methods Choice outpatient service atrial fibrillation trembles the patient 344 eases,plants stochastically according to sickness divides into two groups,takes the rope separately Sotalol and Amiedarone,the adjustment medication dosage treats and observes for 12 months,carries on the material summary.Results The rope Sotalol group and the Amiedarone group each is 172 people,the rope Sotalol group atrial fibrillation trembles transfers sinous rhythm 45 peoples,transfers rate 26.2%,recurs 5 patients,after transfers sinous rhythm maintenance rate 88.9% ; Amiodarone,group atrial fibrillation trembles transfers sinus rhythm 41 people,transfers rate 23.8%,recurs 2 patients,after transfers sinous rhythm maintenance rate 95.1% ; Conclusion Sotalol group treats atrial fibrillation trembles rate to be higher than the Amiedarone group,after transfers sinous rhythm maintenance rate Amiedarone group to be higher than Sotalol group.